NASDAQ$ONC
BeiGene Ltd-ADR · Q1 2024 earnings
Q1 2024 earnings · · Investor relations
Briefing
BeiGene reported strong financial results driven by global revenue growth and made progress towards sustainable profitability.
BeiGene reported a strong first quarter in 2024, with total revenues of $752 million, an increase of 68% compared to the same period in 2023. The company's growth was primarily driven by BRUKINSA product sales in the U.S. and Europe. BeiGene is also making significant improvements in operating leverage as it progresses towards sustainable profitability.
- Total revenues reached $752 million, with product revenue of $747 million, reflecting an 82% increase year-over-year.
- BRUKINSA revenue was $489 million, with U.S. and Europe growth of 153% and 243%, respectively.
- TEVIMBRA sales totaled $145 million, a 26% increase compared to the prior-year period.
- The company significantly improved operating leverage and is progressing towards sustainable profitability.
Headline financials
Revenue & EPS history
BeiGene · Revenue · Quarterly
$752M
Revenue by segment
BeiGene · $211M total across 1 segment · Q1 2023
- BRUKINSA$211M+102.7%100.0%
Forward guidance
This press release contains forward-looking statements regarding BeiGene’s ability to advance its pipeline of therapies, anticipated clinical activities, the opening date of BeiGene’s biologics manufacturing facility, BeiGene’s progress towards sustainable profitability, and BeiGene’s plans, commitments, aspirations and goals.
Tailwinds
- Advance pipeline of therapies for hematologic malignancies.
- Rapidly advance pipeline of solid tumor therapies to solidify its reputation as a global oncology innovator.
- Anticipated clinical activities and read outs.
- Opening date of BeiGene’s biologics manufacturing facility and clinical R&D center in Hopewell, New Jersey.
- BeiGene’s progress towards sustainable profitability.
Headwinds
- BeiGene’s ability to demonstrate the efficacy and safety of its drug candidates.
- The clinical results for its drug candidates, which may not support further development or marketing approval.
- Actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials and marketing approval.
- BeiGene’s ability to achieve commercial success for its marketed medicines and drug candidates, if approved.
- BeiGene's ability to obtain and maintain protection of intellectual property for its medicines and technology.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2024
-0.1%
Avg return
Earnings day
+0.1%
Avg return
5 days after
-2.0%
Avg return
30 days after
40%
16 / 40 earnings
Positive
+15.9%
Q4 2023
Best reaction
-9.6%
Q1 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +5.3% | +4.3% | -9.4% | |
| Q4 2025 | -8.5% | -15.7% | -19.6% | |
| Q3 2025 | +3.4% | +6.9% | +0.5% | |
| Q1 2025 | -3.9% | -3.5% | +5.8% | |
| Q4 2024 | +7.5% | -0.7% | +3.2% | |
| Q3 2024 | +1.4% | -4.5% | +1.4% | |
| Q2 2024 | +6.8% | +10.9% | +11.7% | |
| Q1 2024 | -2.0% | -2.2% | -4.9% | |
| Q4 2023 | +15.9% | +6.4% | -0.0% | |
| Q3 2023 | -0.5% | +0.7% | -12.6% | |
| Q2 2023 | -0.3% | -9.2% | +1.2% | |
| Q1 2023 | -5.7% | -7.3% | -14.2% | |
| Q4 2022 | +4.2% | +11.9% | +2.9% | |
| Q3 2022 | -0.2% | +7.3% | +4.2% | |
| Q2 2022 | +14.6% | +16.4% | -1.7% | |
| Q1 2022 | -9.6% | -11.9% | -12.9% | |
| Q4 2021 | -2.5% | -0.8% | -10.8% | |
| Q3 2021 | -2.3% | -1.1% | -15.9% | |
| Q2 2021 | -6.3% | -8.1% | -2.0% | |
| Q1 2021 | +2.2% | +5.4% | +15.7% | |
| Q4 2020 | -4.4% | -8.5% | -3.0% | |
| Q3 2020 | -3.6% | -7.2% | -26.8% | |
| Q2 2020 | -2.9% | -7.7% | +5.8% | |
| Q1 2020 | +1.0% | +6.0% | +9.6% | |
| Q4 2019 | -2.3% | -3.2% | -21.8% | |
| Q3 2019 | +2.9% | +3.4% | -6.5% | |
| Q2 2019 | +1.6% | +3.9% | -7.8% | |
| Q1 2019 | +14.2% | +13.6% | +4.3% | |
| Q4 2018 | -2.1% | +8.4% | -5.7% | |
| Q3 2018 | +1.4% | -11.2% | +10.4% | |
| Q2 2018 | -3.7% | -4.4% | -4.7% | |
| Q1 2018 | -5.2% | +4.3% | +20.9% | |
| Q4 2017 | -4.8% | +0.3% | +11.3% | |
| Q3 2017 | -5.5% | -0.0% | +10.4% | |
| Q2 2017 | -7.3% | -9.0% | -7.4% | |
| Q1 2017 | -1.3% | +0.7% | +3.9% | |
| Q4 2016 | -2.8% | -4.1% | -3.1% | |
| Q3 2016 | -4.7% | +7.4% | -19.5% | |
| Q2 2016 | +0.8% | +6.0% | +11.0% | |
| Q4 2015 | +5.9% | — | — | |
| Q3 2015 | — | — | — | |
| Q2 2015 | — | — | — | |
| Q1 2015 | — | — | — | |
| Q4 2014 | — | — | — | |
| Q3 2014 | — | — | — | |
| Q2 2014 | — | — | — | |
| Q1 2014 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro